22:35 , Feb 7, 2019 |  BC Extra  |  Preclinical News

Novo, MIT develop oral biologic delivery device

A team including Massachusetts Institute of Technology and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) scientists have developed an ingestible pill-sized device that can deliver drugs, including insulin, directly to the gastric mucosa. The device --...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
18:35 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); B cell lymphoma; mantle cell lymphoma (MCL) Patient sample and mouse studies suggest inhibiting the pentose phosphate pathway with PP2A inhibitor LB-100, inhibition of G6PD or synergistic combination of both,...
23:24 , Aug 3, 2017 |  BC Innovations  |  Tools & Techniques

The other side of the Rubicon

In the end, it might be the efficacy that guides the ethics. By showing that editing of human embryos using CRISPR can be performed efficiently and without leading to the much-feared slew of off-target cuts,...
19:40 , Apr 14, 2017 |  BC Week In Review  |  Clinical News

Personal Genome Service Genetic Health Risk (GHR) test regulatory update

FDA approved 23andMe's PGS Genetic Health Risk (GHR) test to assess genetic risk for 10 diseases and conditions. The approved indications are Parkinson’s disease (PD), late-onset Alzheimer’s disease (AD), celiac disease, alpha-1 antitrypsin ( AAT...
21:30 , Mar 10, 2017 |  BC Extra  |  Clinical News

China scientists edit genes with CRISPR in viable human embryos

Scientists in China published a paper describing what is believed to be the first use of CRISPR- Cas9 gene editing in viable human embryos. The manuscript, published in Molecular Genetics and Genomics , showed a...
08:00 , Nov 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glucose-6-phosphate dehydrogenase (G6PD)

Cancer INDICATION: Lung cancer Studies in patient samples, cell culture and mice suggest inhibiting G6PD glycosylation could help treat lung cancer. Lung tissue from patients with lung cancer had higher levels of glycosylated G6PD in...
08:00 , Nov 21, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Mouse model of hemolytic anemia induced by malaria drugs A mouse model of hemolytic anemia could be useful for evaluating the...
07:00 , Aug 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Glucose-6-phosphate dehydrogenase (g6pd) In vitro studies identified Plasmodium falciparum g6pd inhibitors that could help treat malaria. In a high throughput screen of about...
07:00 , May 10, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors Glucose-6-phosphate dehydrogenase (G6PD) An SAR study identified G6PD inhibitors that could be useful for treating solid tumors. Previous studies suggested G6PD is critical...